Johnson & Johnson (JNJ.US) shares are gaining 4% during today's session, after the drug and healthcare products manufacturer reported second-quarter results that exceeded analysts' expectations. On the other hand, the company lowered its adjusted earnings per share forecast for the full year due to costs associated with mergers and acquisitions resulting from recent transactions. However, it seems that in the eyes of investors, higher costs incurred now will be offset by higher profits in the future.
ANNUAL FORECAST
- Expected adjusted earnings per share (EPS) $9.97 to $10.07, previously $10.57 to $10.72
- Expected adjusted operating EPS $10 to $10.10, previously $10.60 to $10.75
- Expected revenues between $88 billion to $88.4 billion (unchanged)
SECOND QUARTER RESULTS
- Adjusted EPS $2.82, estimated $2.71
- Revenues $22.45 billion, estimated $22.32 billion
- MedTech revenues $7.96 billion, estimated $8.22 billion
- Pharmaceutical division revenues $14.49 billion, estimated $14.08 billion
Source: xStation
Daily Summary: A grim end to a difficult week
Without Jensen: Markets at the Mercy of the Fed
US OPEN: Selling pressure eases, Anthropic gives back post-IPO gains
Market Wrap: Global stocks post 7th consecutive session of losses, Anthropic failed to reassure the market (20.11.2026)